MA44383A - Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer - Google Patents
Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancerInfo
- Publication number
- MA44383A MA44383A MA044383A MA44383A MA44383A MA 44383 A MA44383 A MA 44383A MA 044383 A MA044383 A MA 044383A MA 44383 A MA44383 A MA 44383A MA 44383 A MA44383 A MA 44383A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazolylamino
- cancer
- treatment
- benzimidazole derivative
- jak1 inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200684P | 2015-08-04 | 2015-08-04 | |
| EP16750326.7A EP3331873B1 (fr) | 2015-08-04 | 2016-07-28 | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer |
| PCT/US2016/044410 WO2017023672A1 (fr) | 2015-08-04 | 2016-07-28 | Composés 4-(3-pyrazolylamino)-benzimidazole et leur utilisation en tant qu'inhibiteurs de jak1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44383A true MA44383A (fr) | 2019-01-23 |
| MA44383B1 MA44383B1 (fr) | 2019-08-30 |
Family
ID=56618268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44383A MA44383B1 (fr) | 2015-08-04 | 2016-07-28 | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9556153B1 (fr) |
| EP (1) | EP3331873B1 (fr) |
| JP (1) | JP6470869B2 (fr) |
| KR (1) | KR102032792B1 (fr) |
| CN (1) | CN108026076B (fr) |
| AR (1) | AR105400A1 (fr) |
| AU (1) | AU2016302748B2 (fr) |
| BR (1) | BR112017028240B1 (fr) |
| CA (1) | CA2990471C (fr) |
| CY (1) | CY1121909T1 (fr) |
| DK (1) | DK3331873T3 (fr) |
| EA (1) | EA033572B1 (fr) |
| ES (1) | ES2743499T3 (fr) |
| HR (1) | HRP20191227T1 (fr) |
| HU (1) | HUE047037T2 (fr) |
| LT (1) | LT3331873T (fr) |
| MA (1) | MA44383B1 (fr) |
| MD (1) | MD3331873T2 (fr) |
| ME (1) | ME03451B (fr) |
| MX (1) | MX2018001306A (fr) |
| NZ (1) | NZ738247A (fr) |
| PL (1) | PL3331873T3 (fr) |
| PT (1) | PT3331873T (fr) |
| RS (1) | RS58974B1 (fr) |
| SI (1) | SI3331873T1 (fr) |
| TW (1) | TW201718555A (fr) |
| WO (1) | WO2017023672A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013486A1 (fr) * | 2016-07-14 | 2018-01-18 | Eli Lilly And Company | Dérivés de pyrazolylaminobenzimidazole en tant qu'inhibiteurs de jak |
| GB201717260D0 (en) * | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013025628A1 (fr) * | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Composés et procédés d'inhibition de janus kinase |
| KR20150008907A (ko) * | 2012-06-14 | 2015-01-23 | 일라이 릴리 앤드 캄파니 | Jak1 및 jak2의 억제제 |
| GB201401086D0 (en) * | 2014-01-23 | 2014-03-12 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
-
2016
- 2016-07-20 AR ARP160102192A patent/AR105400A1/es unknown
- 2016-07-21 TW TW105123089A patent/TW201718555A/zh unknown
- 2016-07-28 PL PL16750326T patent/PL3331873T3/pl unknown
- 2016-07-28 CN CN201680045255.7A patent/CN108026076B/zh active Active
- 2016-07-28 BR BR112017028240-2A patent/BR112017028240B1/pt active IP Right Grant
- 2016-07-28 RS RS20190876A patent/RS58974B1/sr unknown
- 2016-07-28 ME MEP-2019-196A patent/ME03451B/fr unknown
- 2016-07-28 DK DK16750326.7T patent/DK3331873T3/da active
- 2016-07-28 LT LTEP16750326.7T patent/LT3331873T/lt unknown
- 2016-07-28 ES ES16750326T patent/ES2743499T3/es active Active
- 2016-07-28 HU HUE16750326A patent/HUE047037T2/hu unknown
- 2016-07-28 MA MA44383A patent/MA44383B1/fr unknown
- 2016-07-28 KR KR1020187003079A patent/KR102032792B1/ko active IP Right Grant
- 2016-07-28 NZ NZ738247A patent/NZ738247A/en unknown
- 2016-07-28 PT PT16750326T patent/PT3331873T/pt unknown
- 2016-07-28 MX MX2018001306A patent/MX2018001306A/es active IP Right Grant
- 2016-07-28 JP JP2018502720A patent/JP6470869B2/ja active Active
- 2016-07-28 EA EA201792676A patent/EA033572B1/ru not_active IP Right Cessation
- 2016-07-28 US US15/221,649 patent/US9556153B1/en active Active
- 2016-07-28 AU AU2016302748A patent/AU2016302748B2/en active Active
- 2016-07-28 SI SI201630314T patent/SI3331873T1/sl unknown
- 2016-07-28 WO PCT/US2016/044410 patent/WO2017023672A1/fr active Application Filing
- 2016-07-28 EP EP16750326.7A patent/EP3331873B1/fr active Active
- 2016-07-28 CA CA2990471A patent/CA2990471C/fr active Active
- 2016-07-28 MD MDE20180584 patent/MD3331873T2/ro unknown
-
2019
- 2019-07-08 HR HRP20191227TT patent/HRP20191227T1/hr unknown
- 2019-08-16 CY CY20191100882T patent/CY1121909T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA41291A (fr) | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer | |
| MA45192A (fr) | Traitement d'association | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| MA46652A (fr) | Polythérapie pour l'inhibition de c3 |